对两种β-拉帕衍生物的抗癌作用和毒基因组安全性的新见解
José Rivaldo De Lima1, Alexandre José Da Silva Góes1, Elizabeth Fernanda De Oliveira Borba1
1Departamento de Antibióticos, Universidade Federal de Pernambuco, Recife 50670-420, Brazil.
Pharmaceuticals (Basel, Switzerland)
|June 27, 2025
概括
新的β-拉帕衍生物 (BV3和BV5) 对固体瘤具有强大的抗癌作用,与原始化合物相比,其选择性和安全性得到改善.
科学领域:
- 在瘤学瘤学.
- 药用化学 医学化学
- 药理学 药理学是指药理学的学科.
背景情况:
- β-Lapachone (β-lap) 是一种具有抗瘤特性的o-naphthoquinone,但其临床用途因溶解性差和毒性有限.
- 西米卡巴衍生物BV3和BV5在白血病细胞中表现出增强的选择性和有效性.
- 这项研究研究了BV3和BV5在固体瘤中的治疗潜力.
研究的目的:
- 在固体瘤模型中评估BV3和BV5的抗癌疗效.
- 阐明由这些衍生品诱导的瘤细胞死亡机制.
- 调查蛋白质激酶抑制对它们的作用的参与.
- 评估BV3和BV5.5的毒性遗传安全概况.
主要方法:
- 对各种癌症和非癌症细胞系进行了细胞毒性测试,并选择了HeLa细胞进行进一步研究.
- 使用流细胞计和形态分析来确定细胞死亡的模式.
- 进行了体外和体内酶抑制试验.
- 进行基因毒性评估以评估毒性遗传安全性.
主要成果:
- 与β-lap相比,BV3和BV5显著抑制了癌细胞的增殖 (IC50:2.836.9μM),并且在HeLa细胞中表现出优越的选择性.
- 在用BV3和BV5.5治疗的HeLa细胞中观察到亡和/或亡.
- BV3和BV5有效抑制了JAK3和GSK3β激酶,这在体研究中得到证实.
- 基因毒性测试显示了有利的安全性,尽管BV5在高度下显示出潜在的基因毒性.
结论:
- BV3和BV5对固体瘤具有显著的抗癌潜力.
- 它们的作用机制包括抑制特定的蛋白激酶 (JAK3和GSK3β).
- 衍生品显示出有利的选择性和相对安全性,支持进一步的临床研究.
相关概念视频
Mutagenicity and Carcinogenicity
1.4K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.4K
Adrenergic Antagonists: ɑ and β-Receptor Blockers
635
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
635
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K

![Chemical-Induced Skin Carcinogenesis Model Using Dimethylbenz[a]Anthracene and 12-O-Tetradecanoyl Phorbol-13-Acetate DMBA-TPA](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F60445.jpg&w=3840&q=50)
